Innovating Clinical Trials
de Liam Eves and Ted Trafford
Último episodio
ICT Ep 2.41: Robert Goldman on "Optimism Is Not an Enrollment Plan"…
ICT Ep 2.41: Robert Goldman on "Optimism Is Not an Enrollment Plan"…
Sobre este podcast
Welcome to Innovating Clinical Trials, the podcast designed for clinical research professionals eager to deepen their understanding of clinical trials through concise, insightful segments. Join your hosts, Liam Eves and Ted Trafford, as they uncover the core issues in clinical research, reflect on the industry, and challenge conventional wisdom.
Ted Trafford - https://probitymedical.com/
With 30 years of experience in clinical research, Ted serves as the Director of Business Development, driving business growth and leading Feasibility and Site Relationship teams at Probity Medical Research, a clinical trial site administrative support company with a consortium of 75+ sites across four countries. As a writer and speaker, Ted contributes to thought leadership and strategic initiatives in the clinical trials industry, leveraging his extensive experience and creative approach to drive meaningful discussion and progress for Sponsors, CROs, Sites and Technology Vendors.
Liam Eves - https://www.theendpointpodcast.com/
Liam's held executive roles in SMOs and CROs, and led all major functions of trial delivery. His journey into the field began unexpectedly after an injury ended his career as a professional footballer. Over the years Liam has optimized trial delivery methods / systems for effective enrollment and trial delivery. Currently, he focuses on building and advising companies in the clinical trial space.
Opinions expressed are those of the participants and not their employers.
Episodios
Los 20 episodios más recientes de 70
- ICT Ep 2.41: Robert Goldman on "Optimism Is Not an Enrollment Plan" (Part 1/3) · 18 min · Temporada 2 Episodio 41In Part 1 of this three-part conversation, Liam and Ted sit down with Robert Goldman, Vice President and Global Head of Clinical Operations at Contraline, who brings nearly 20…
- ICT Ep 2.40: Duncan Shaw on the AI Translation Trap: Why the Human “Last Mile” Still Matters When the Stakes Are High (Part 3/3) · 17 min · Temporada 2 Episodio 40In Part 3 of this three-part conversation, Liam and Ted wrap up their discussion with Duncan, President at DTS Language Services about AI, risk mitigation, and the human factors…
- ICT Ep 2.39: Duncan Shaw on the Translation “Quilt Factor”: How Inconsistency Can Erode Patient Trust and Derail Trial Operations (Part 2/3) · 17 min · Temporada 2 Episodio 39In Part 2 of this three-part conversation, Liam and Ted continue their discussion with Duncan, President at DTS Language Services about patient trust, consistency, and the…
- ICT Ep 2.38: Duncan Shaw on the Hidden Risks of Clinical Trial Translation: What Happens With One Wrong Word (Part 1/3) · 16 min · Temporada 2 Episodio 38In Part 1 of this three-part conversation, Liam and Ted sit down with Duncan, President at DTS Language Services, to talk about the good, the bad, and the ugly of clinical trial…
- ICT Ep 2.37: "You Lose a Patient You Didn't Even Know You Lost" Why No One Owns Recruitment · 18 min · Temporada 2 Episodio 37In this episode, Ted introduces the “ENROLL Corporation” (Everyone Needed for Recruitment Optimization Leadership and Logistics) an imaginary joint venture owned by the sponsor…
- ICT Ep 2.36: Robin Piazza on ICH E6 R3 and the New Rules for Safety Oversight (Part 2/2) · 16 min · Temporada 2 Episodio 36In Part 2, Robin Piazza, Liam and Ted get specific about what good safety oversight actually looks like in practice, and what sponsors are getting wrong under the shift from FDA…
- ICT Ep 2.35: Robin Piazza on the Safety Oversight Gap No One's Training For (Part 1/2) · 20 min · Temporada 2 Episodio 35Robin Piazza reached out to us directly with this topic suggestion, and we’re glad she did. In Part 1 of this two-part conversation, Liam and Ted sit down with Robin, Founder of…
- ICT Ep 2.34: Study Startup Delays Are a Symptom: What Happens When You Stop and Listen · 16 min · Temporada 2 Episodio 34In this episode, Liam and Ted ask a simple “what if”, what if the industry took the time to really listen? Ted starts with a study startup delay that looks like a tooling problem…
- ICT Ep 2.33: Steve Wimmer on the Button That Almost Killed a Recruitment Campaign (Part 3/3) · 19 min · Temporada 2 Episodio 33Each episode in this series has built toward this one: what does all of this look like from the other side of the table? In the final part of this series, the Steve Wimmer shares…
- ICT Ep 2.32: Steve Wimmer on Why Recruitment Campaigns Fall Apart at the Site (Part 2/3) · 20 min · Temporada 2 Episodio 32Part 1 was about why storytelling matters, part 2 is about how to actually operationalize it and Steve Wimmer brings a framework that reframes the entire recruitment funnel…
- ICT Ep 2.31: Steve Wimmer on Why Storytelling Is What Sponsors Keep Getting Wrong (Part 1/3) · 19 min · Temporada 2 Episodio 31Liam and Ted sit down with Steve Wimmer, who brings seven years of direct-to-patient recruitment advertising experience. They discuss why storytelling in clinical trial…
- Ep 2.30: Scott Burgher on Where AI Actually Helps Patient Recruitment (Part 3/3) · 14 min · Temporada 2 Episodio 30In the final part of this three-part conversation, Liam and Ted close things out with Scott Burgher, Director of Patient Operations at Quest Diagnostics, looking ahead at where…
- Ep 2.29: "That's Not a Performance Problem, It's a Structural One" Scott Burgher on Why Sites Stop Recruiting (Part 2/3) · 16 min · Temporada 2 Episodio 29In Part 2 of this three-part conversation, Liam and Ted continue with Scott Burgher, Director of Patient Operations at Quest Diagnostics, going deeper into why recruitment keeps…
- Ep 2.28 Scott Burgher on Why 86% of Trials Miss Their Enrollment Deadline (Part 1/3) · 20 min · Temporada 2 Episodio 28In Part 1 of this three-part conversation, Liam and Ted sit down with Scott Burgher, Director of Patient Operations at Quest Diagnostics, who brings over 20 years of patient…
- Ep 2.27: 31 Years of Clinical Trials, Here's What Ted Trafford Knows for Sure · 16 min · Temporada 2 Episodio 30In this special episode, we mark Ted Trafford's 31st year in clinical trials with a candid reflection on what three decades in this industry actually teaches you. It started with…
- Ep 2.26: Lasagna's Law and Building Recruitment Forecasts You Can Actually Trust · 19 min · Temporada 2 Episodio 29Every trial starts with a number on a slide, patients needed, months allotted, a clean straight line on a chart. Liam and Ted pull that line apart in this episode, starting with…
- Ep. 2.25 The Burdens Still Breaking Clinical Trials: 50-Page Consents, Broken Tech, and Stolen CRCs · 15 min · Temporada 2 Episodio 25In this episode, Ted opens with a poem that captures the persistent, compounding burden on clinical trial sites: 50-page consents, non-functional tech, poached CRCs, financial…
- Ep 2.24 The Decision Threshold Matrix: Why Patient Motivation Isn't Fixed and What It Means for Trial Recruitment · 21 min · Temporada 2 Episodio 24In this episode, Liam and Ted explore one of the most underexamined problems in clinical trial recruitment: patient motivation is not static. Drawing on real-world experience…
- Ep 2.23: Jill Fikowski on Why Participants Drop Out and What to Do About It (3/3) · 14 min · Temporada 2 Episodio 23In the final episode of our three-part series with Jill Fikowski, founder and CEO of Changemark Research + Evaluation, we get into one of the most persistent problems in clinical…
- Ep 2.22: Jill Fikowski on Designing Trials That Communities Actually Want to Join (2/3) · 21 min · Temporada 2 Episodio 22In Part 2 of our conversation with Jill Fikowski, founder and CEO of Changemark Research + Evaluation, we get into what good community engagement actually looks like in practice…
